Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will 2009 Be The Year Of M&As For Japanese Drug Makers In Antibody Space?

This article was originally published in PharmAsia News

Executive Summary

The therapeutic market for monoclonal antibodies has grown exponentially since 2000, and Japanese pharmas, like counterparts in the U.S. and Europe, are looking to antibody drug development as a key-growth driver
Advertisement

Related Content

Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
Chugai To Deploy Chiome’s MAb Generation Technology
Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Advertisement
UsernamePublicRestriction

Register

SC069931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel